Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 19/20 | 0.68 |
| ▸ | ADAM17 | P78536 | 19/20 | 0.68 |
| ▸ | MMP2 | P08253 | 12/20 | 0.57 |
| ▸ | MMP14 | P50281 | 11/20 | 0.57 |
| ▸ | MMP1 | P03956 | 8/20 | 0.53 |
| ▸ | MMP9 | P14780 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7360808 | 0.89 | ADAM17 (0.56) | MMP13ADAM17MMP2MMP14MMP1 | |
| SCHEMBL6263926 | 0.86 | ADAM17 (0.71) | MMP13ADAM17MMP2MMP14MMP1 | |
| SCHEMBL3949076 | 0.81 | ADAM17 (0.47) | MMP13ADAM17MMP2MMP14MMP1 | |
| SCHEMBL7040196 | 0.81 | ADAM17 (1.00) | MMP13ADAM17MMP2MMP14MMP1 | |
| SCHEMBL3949307 | 0.80 | MMP13 (0.67) | MMP13ADAM17MMP2MMP14MMP1 | |
| SCHEMBL3946150 | 0.79 | ADAM17 (1.00) | MMP13ADAM17MMP2MMP14MMP1 | |
| SCHEMBL6507094 | 0.79 | ADAM17 (0.75) | MMP13ADAM17MMP2MMP14MMP1 | |
| SCHEMBL6261987 | 0.78 | ADAM17 (0.71) | MMP13ADAM17MMP2MMP14MMP1 | |
| SCHEMBL7427317 | 0.78 | ADAM17 (0.79) | MMP13ADAM17MMP2MMP14MMP1 | |
| SCHEMBL6755198 | 0.76 | MMP13 (0.56) | MMP13ADAM17MMP2MMP14MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147085-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | WYETH CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | AMERICAN CYANAMID COMPANY | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086890-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors | MMP17, MMP1, MMP9 | MMP13 16/4885ADAM17 12/4885MMP2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.